Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2.

Abstract

Bilateral vestibular schwannomas are the hallmark of neurofibromatosis type 2 (NF2), and these tumors impair hearing and frequently lead to deafness. Neurosurgical intervention, the only established treatment, often damages the vestibular nerve. We report 2 cases in which treatment with bevacizumab (for 3 months in one case and 6 months in the other) induced regression of progressive vestibular schwannomas by more than 40% and substantially improved hearing in the patient treated for 6 months. Bevacizumab therapy may thus provide an effective treatment for progressive vestibular schwannomas in patients with NF2.

• Authors: Victor-Felix Mautner, Rosa Nguyen, Hannes Kutta, Carsten Fuensterer, Carsten Bokemeyer, Christian Hagel, Reinhard E Friedrich, Jens Panse
• Journal: Neuro-oncology (Neuro Oncol) Vol. 12 Issue 1 Pg. 14-8 (Jan 2010) ISSN: 1523-5866 [Electronic] England
• PMID: 20150363 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Antineoplastic Agents
• Bevacizumab

Topics

• Adolescent
• Antibodies, Monoclonal (therapeutic use)
• Antibodies, Monoclonal, Humanized
• Antineoplastic Agents (therapeutic use)
• Audiometry
• Bevacizumab
• Hearing Loss (drug therapy, etiology, pathology)
• Humans
• Magnetic Resonance Imaging
• Male
• Neurofibromatosis 2 (complications, drug therapy, pathology)
• Neuroma, Acoustic (drug therapy, etiology, pathology)
• Young Adult